Benitec生物制药 BNTC 深 沪
已收盘 10-17 16:00:00 美东时间
15.65
-0.050
-0.32%
华盛通- 最 高15.9623
- 今 开15.70
- 成交量 3.35万股
- 最 低 15.21
- 昨 收 15.70
- 总市值 4.11亿
- 52周最高 17.15
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9.10
- 委 比 -4.14%
- 总股本 2625.05万
- 历史最高 5609.5744
- 量 比 0.64
- 振 幅 4.79%
- 历史最低 2.227
- 每 手 1
- 风险率 1.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $20 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20 price target.
09-24 21:02
Benitec报告GAAP每股收益为-1.05美元
Benitec公司（NASDAQ：BNTC）报告GAAP每股收益为-1.05美元，而预期为每股收益0.72美元。截至2025年6月30日，该公司持有977...
09-23 23:22
Benitec GAAP EPS of -$1.05 beats by $0.72
Benitec press release (NASDAQ:BNTC): FY GAAP EPS of -$1.05 beats by $0.72. As of June 30, 2025, the company had $97.7 million in cash and cash equivalents. More on Benitec Seeking Alpha’s Quant Rating...
09-23 12:48
Benitec Biopharma Reports 2025 Financial Results and Progress
Benitec Biopharma ( ($BNTC) ) has released its Q4 earnings. Here is a breakdown...
09-23 11:52
Benitec Biopharma files $200M mixed securities shelf
Benitec Biopharma (NASDAQ:BNTC) filed $200M mixed securities shelf. Filing More on Benitec Seeking Alpha’s Quant Rating on Benitec Financial information for Benitec
09-23 05:27
Benitec Biopharma Q4 EPS $0.00 Beats $(0.33) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.33) by 100.3 percent. This is a 100.17 percent increase over losses of $(0.60) per share
09-23 04:08
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
Oppenheimer Maintains Outperform on Benitec Biopharma, Lowers Price Target to $29
Oppenheimer analyst Andreas Argyrides maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and lowers the price target from $35 to $29.
09-16 23:56
